Nov 2026 $4 M No. 7 $2 to $10 million 4
Linnaeus Therapeutics, Inc.: Raise no. 7, Nov 2026 × Investors in this round 4 investors had bought by the notice of Nov 18, 2026: 4 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $4 M of $10 M offered; $6 M still to sell
Smallest investment taken $1
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Chris Arendt · Director James 30 Washington Avenue, Suite F · Director John Lepping · Director Michael Poisel · Director Patrick Mooney · Director Todd Thomson · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Anthony Gruzdis, Attorney-in-fact. Source: SEC Form D, newest notice filed Nov 18, 2026. Read the notice at the SEC .
equity SEC Feb 2026 $5 M No. 6 $2 to $10 million 26
Linnaeus Therapeutics, Inc.: Raise no. 6, Feb 2026 × Investors in this round 26 investors had bought by the notice of Apr 2, 2026: 26 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $5 M of $10 M offered; $5 M still to sell
Smallest investment taken $1
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Patrick Mooney · Executive Officer, Director Chris Arendt · Director James Demetriades · Director John Lepping · Director Michael Poisel · Director Todd Thomson · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Anthony Gruzdis, Attorney-in-fact. Source: SEC Form D and 3 amendments, newest notice filed Apr 2, 2026. Read the notice at the SEC .
equity SEC Aug 2024 $6 M No. 5 $2 to $10 million 12
Linnaeus Therapeutics, Inc.: Raise no. 5, Aug 2024 × Investors in this round 12 investors had bought by the notice of Dec 26, 2024: 12 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $6 M of $7 M offered; $1 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited Section 4(a)(5): accredited investors only, up to $5 million, no public advertising
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Patrick T. Mooney · Executive Officer Chris D. Arendt · Director James T. Demetriades · Director Michael D. Poisel · Director Todd T. Thomson · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Mariel J. Giletto, Attorney-in-fact. Source: SEC Form D and 1 amendment, newest notice filed Dec 26, 2024. Read the notice at the SEC .
equity SEC Jan 2023 $3 M No. 4 $2 to $10 million 8
Linnaeus Therapeutics, Inc.: Raise no. 4, Jan 2023 × Investors in this round 8 investors had bought by the notice of Jan 26, 2023: 8 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $3 M offered
Smallest investment taken $15,700
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited Section 4(a)(5): accredited investors only, up to $5 million, no public advertising
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Patrick T. Mooney · Executive Officer, Director Michael D. Poisel · Director Nicholas T. Iatropoulos · Director Todd T. Thomson · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Mariel J. Giletto, Attorney-in-fact. Source: SEC Form D, newest notice filed Jan 26, 2023. Read the notice at the SEC .
equity SEC Aug 2021 $4 M No. 3 $2 to $10 million 15
Linnaeus Therapeutics, Inc.: Raise no. 3, Aug 2021 × Investors in this round 15 investors had bought by the notice of Aug 24, 2021: 15 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $4 M of $4 M offered
Smallest investment taken $24,999
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited Section 4(a)(5): accredited investors only, up to $5 million, no public advertising
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Patrick T. Mooney · Executive Officer, Director Michael D. Poisel · Director Nicholas T. Iatropoulos · Director Todd T. Thomson · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Mariel J. Giletto, Attorney-in-fact. Source: SEC Form D, newest notice filed Aug 24, 2021. Read the notice at the SEC .
equity SEC Jan 2019 $2 M No. 2 $2 to $10 million 3
Linnaeus Therapeutics, Inc.: Raise no. 2, Jan 2019 × Investors in this round 3 investors had bought by the notice of Feb 8, 2019: 3 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M (amount offered: indefinite)
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited Section 4(a)(5): accredited investors only, up to $5 million, no public advertising
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people $28,919 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Christopher D. Natale · Executive Officer Patrick T. Mooney · Executive Officer, Director Michael D. Poisel · Director Nicholas D. Iatropoulos · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “Approximately $28,919 of the proceeds may be used to repay the remaining principal of a promissory note made to the issuer by the issuer's CEO. The decision to repay the principal will be at the discretion of the issuer's board of directors.”Signed by Adam Chelminiak, Attorney-in-fact. Source: SEC Form D, newest notice filed Feb 8, 2019. Read the notice at the SEC .
equity SEC Aug 2018 $2 M No. 1 $2 to $10 million 4
Linnaeus Therapeutics, Inc.: Raise no. 1, Aug 2018 × Investors in this round 4 investors had bought by the notice of Sep 7, 2018: 4 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M (amount offered: indefinite)
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited Section 4(a)(5): accredited investors only, up to $5 million, no public advertising
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people $100,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Christopher D. Natale · Executive Officer Patrick T. Mooney · Executive Officer, Director Michael D. Poisel · Director Nicholas D. Iatropoulos · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “A second tranche of $2,160,000 will be sold within the next 9 months if the issuer achieves certain milestone events.”On the use of proceeds: “Approximately $100,000 of the proceeds of this offering may be used to repay the principal of a promissory note made to the issuer by the issuer's CEO. The decision to repay the principal will be at the discretion of the issuer's board of directors.”Signed by Adam Chelminiak, Attorney-in-fact. Source: SEC Form D, newest notice filed Sep 7, 2018. Read the notice at the SEC .
equity SEC